- Home
- BJRI vs EMBC Comparison
BJRI vs EMBC Comparison
Compare BJRI & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- EMBC
- Stock Information
- Founded
- BJRI 1978
- EMBC 1924
- Country
- BJRI United States
- EMBC United States
- Employees
- BJRI N/A
- EMBC N/A
- Industry
- BJRI Restaurants
- EMBC Medical/Dental Instruments
- Sector
- BJRI Consumer Discretionary
- EMBC Health Care
- Exchange
- BJRI Nasdaq
- EMBC Nasdaq
- Market Cap
- BJRI 776.3M
- EMBC 788.4M
- IPO Year
- BJRI 1996
- EMBC N/A
- Fundamental
- Price
- BJRI $29.95
- EMBC $15.06
- Analyst Decision
- BJRI Hold
- EMBC Buy
- Analyst Count
- BJRI 6
- EMBC 2
- Target Price
- BJRI $40.17
- EMBC $18.50
- AVG Volume (30 Days)
- BJRI 520.4K
- EMBC 488.5K
- Earning Date
- BJRI 10-30-2025
- EMBC 08-08-2025
- Dividend Yield
- BJRI N/A
- EMBC 3.96%
- EPS Growth
- BJRI N/A
- EMBC 18.26
- EPS
- BJRI 1.17
- EMBC 1.42
- Revenue
- BJRI $1,383,611,000.00
- EMBC $1,102,500,000.00
- Revenue This Year
- BJRI $5.36
- EMBC N/A
- Revenue Next Year
- BJRI $2.94
- EMBC N/A
- P/E Ratio
- BJRI $26.17
- EMBC $10.67
- Revenue Growth
- BJRI 4.07
- EMBC N/A
- 52 Week Low
- BJRI $28.92
- EMBC $9.20
- 52 Week High
- BJRI $47.02
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- BJRI 28.68
- EMBC 64.69
- Support Level
- BJRI $30.89
- EMBC $14.92
- Resistance Level
- BJRI $34.56
- EMBC $15.44
- Average True Range (ATR)
- BJRI 0.97
- EMBC 0.52
- MACD
- BJRI -0.19
- EMBC -0.09
- Stochastic Oscillator
- BJRI 1.81
- EMBC 66.67
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.